Patents Assigned to Link Genomics, Inc.
  • Fibrosis drug
    Patent number: 12138251
    Abstract: The present invention provides a pharmaceutical composition for preventing and/or treating a disease characterized by fibrosis of a cell or a tissue, the pharmaceutical composition comprising a compound represented by formula 1 or a salt thereof, and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: January 30, 2020
    Date of Patent: November 12, 2024
    Assignees: SCIENCE FARM LTD., LINK GENOMICS, INC.
    Inventors: Lin Kurahara, Hironobu Ihn, Masami Otsuka
  • FIBROSIS DRUG
    Publication number: 20220096448
    Abstract: The present invention provides a pharmaceutical composition for preventing and/or treating a disease characterized by fibrosis of a cell or a tissue, the pharmaceutical composition comprising a compound represented by formula 1 or a salt thereof, and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: January 30, 2020
    Publication date: March 31, 2022
    Applicants: SCIENCE FARM LTD., LINK GENOMICS, INC.
    Inventors: Lin KURAHARA, Hironobu IHN, Masami OTSUKA
  • Choroidal neovascularization suppressor or drusen formation suppressor, and method for assessing or screening for same
    Patent number: 10761087
    Abstract: The existent therapeutic drugs for CNV are merely pharmaceuticals for a symptomatic therapy, and therapeutic drugs for radical cure are strongly demanded. Also, a therapeutic drug for Dry AMD does not exist, and therapeutic drugs for radical cure are strongly demanded. The present invention provides a prophylactic and/or therapeutic agent for choroidal neovascularization, containing a compound having an activity of suppressing epithelial-mesenchymal transition in retinal pigment epithelial cells, as an active ingredient. Also, the present invention provides a drusen suppressor comprising a compound having an activity of suppressing epithelial-mesenchymal transition in retinal pigment epithelial cells, as an active ingredient.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: September 1, 2020
    Assignees: LINK GENOMICS, INC., ROHTO Pharmaceutical Co., Ltd.
    Inventors: Shinichiro Niwa, Dai Ogura, Hidemi Mizunuma, Yoko Arai, Takahiro Kurose, Yoshihiro Takai, Yoko Mitsuguchi, Mariyo Moriya
  • Antibody against transporter and use thereof
    Patent number: 9725519
    Abstract: The present invention provides a prophylactic or therapeutic agent for various malignant tumors, including currently intractable solid tumors, which contains an antibody having the ability to bind to human LAT1/CD98 and inducing antibody-dependent cellular cytotoxicity specifically against cancer cells as an active ingredient.
    Type: Grant
    Filed: December 5, 2014
    Date of Patent: August 8, 2017
    Assignees: Kinki University, Link Genomics, Inc.
    Inventors: Takashi Masuko, Shinichiro Niwa, Hidemi Hayashi, Dai Ogura, Takayuki Shindou
  • ANTIBODY AGAINST TRANSPORTER AND USE THEREOF
    Publication number: 20150147278
    Abstract: The present invention provides a prophylactic or therapeutic agent for various malignant tumors, including currently intractable solid tumors, which contains a novel antibody having the ability to bind to human LAT1/CD98 and inducing antibody-dependent cellular cytotoxicity specifically against cancer cells as an active ingredient.
    Type: Application
    Filed: December 5, 2014
    Publication date: May 28, 2015
    Applicants: Kinki University, Link Genomics, Inc.
    Inventors: Takashi Masuko, Shinichiro Niwa, Hidemi Hayashi, Dai Ogura, Takayuki Shindou